论文部分内容阅读
大量的研究证实雄激素与前列腺癌的发生密切相关。研究发现非那雄胺(Finasteride)是一种类固醇5α-还原酶抑制剂,可阻断前列腺组织中的睾酮转变为活性更强的双氢睾酮,从而降低前列腺中的雄激素水平,为前列腺癌的诊断和降低前列腺癌风险提供一种新的可能。来自于美国得克萨斯大学的Ian M Thompson博士及其同事自1994年起开展了一项为期7年的前列腺癌预防试验(PCPT),旨在对非那雄胺是否能降低前列腺癌风险进行研究。参加PCPT研究的受试者均为年龄55岁以上的
A large number of studies have confirmed that androgen closely related to the occurrence of prostate cancer. Finasteride, a steroid 5α-reductase inhibitor, has been shown to block the conversion of testosterone in prostate tissue to the more active dihydrotestosterone, thereby reducing the level of androgen in the prostate, Diagnosis and reduce the risk of prostate cancer provide a new possibility. Dr. Ian M Thompson and colleagues from the University of Texas, USA, conducted a seven-year Prostate Cancer Prevention Trial (PCPT) since 1994 to study whether finasteride can reduce the risk of prostate cancer. All participants in the PCPT study were over 55 years of age